Athena Athena

X
[{"orgOrder":0,"company":"Invetx","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Invetx","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Invetx","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"Invetx","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by Invetx

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Based on AbCellera's successful delivery on multiple discovery campaigns under the original agreement, the scope of the collaboration has been expanded to include multiple new targets over several years.

            Lead Product(s): Monoclonal antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Recipient: AbCellera

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 19, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Series A Financing positions the company for rapid scaling of its novel platform and advancing its portfolio of innovative antibody therapeutics for veterinary use.

            Lead Product(s): Antibody therapeutics

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $25.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health.

            Lead Product(s): Antibodies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Twist Bioscience

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proprietary platform combines industry-leading technologies from partners AbCellera, Twist Bioscience and WuXi Biologics to develop fully species-specific, optimized and half-life-extended monoclonal antibodies (mABs) for veterinary use.

            Lead Product(s): Monoclonal Antibodies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Recipient: AbCellera

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY